Medlife Pharmacy and Compounding, Inc.

CLOSEOUT LETTER Medlife Pharmacy and Compounding, Inc. MARCS-CMS 607417 — November 29, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL CONFIRMED DELIVERY Product: Drugs Recipient: Recipient Name Shar Eshraghi, Pharm.D. Medlife Pharmacy and Compounding, Inc. 6644 Irvine Center Dr. Irvine , CA 92618 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States Dear Dr. Eshraghi: The U.S. Food and Drug Administration has completed an evaluation of your corrective actions in response to our warning letter (Ref CMS 607417) dated April 24, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and the FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV Content current as of: 12/14/2021 Regulated Product(s) Drugs